130 related articles for article (PubMed ID: 30726713)
1. PTBP2 exon 10 inclusion is associated with the progression of CML and it is BCR-ABL1 dependent.
Nandagopalan SR; Agatheeswaran S; Vadlamudi Y; Biswas S; Biswas G; Pattnayak NC; Chakraborty S
Int J Biochem Cell Biol; 2019 Apr; 109():69-75. PubMed ID: 30726713
[TBL] [Abstract][Full Text] [Related]
2. BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia.
Srutova K; Curik N; Burda P; Savvulidi F; Silvestri G; Trotta R; Klamova H; Pecherkova P; Sovova Z; Koblihova J; Stopka T; Perrotti D; Polakova KM
Haematologica; 2018 Dec; 103(12):2016-2025. PubMed ID: 30049824
[TBL] [Abstract][Full Text] [Related]
3. BCR-ABL mediated repression of miR-223 results in the activation of MEF2C and PTBP2 in chronic myeloid leukemia.
Agatheeswaran S; Singh S; Biswas S; Biswas G; Chandra Pattnayak N; Chakraborty S
Leukemia; 2013 Jul; 27(7):1578-80. PubMed ID: 23174904
[No Abstract] [Full Text] [Related]
4. Low-dose staurosporine selectively reverses BCR-ABL-independent IM resistance through PKC-α-mediated G2/M phase arrest in chronic myeloid leukaemia.
Ma D; Wang P; Fang Q; Yu Z; Zhou Z; He Z; Wei D; Yu K; Lu T; Zhang Y; Wang J
Artif Cells Nanomed Biotechnol; 2018; 46(sup3):S208-S216. PubMed ID: 30618318
[TBL] [Abstract][Full Text] [Related]
5. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
6. TOPK is regulated by PP2A and BCR/ABL in leukemia and enhances cell proliferation.
Uchida E; Suwa S; Yoshimoto R; Watanabe K; Kasama T; Miura O; Fukuda T
Int J Oncol; 2019 May; 54(5):1785-1796. PubMed ID: 30864683
[TBL] [Abstract][Full Text] [Related]
7. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
8. Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemia.
Foroni L; Gerrard G; Nna E; Khorashad JS; Stevens D; Swale B; Milojkovic D; Reid A; Goldman J; Marin D
Am J Hematol; 2009 Aug; 84(8):517-22. PubMed ID: 19544476
[TBL] [Abstract][Full Text] [Related]
9. High frequency of BTG1 deletions in patients with BCR-ABL1-positive acute leukemia.
Xie J; Wang Q; Wang Q; Yao H; Wen L; Ma L; Wu D; Chen S
Cancer Genet; 2014 May; 207(5):226-30. PubMed ID: 24998463
[TBL] [Abstract][Full Text] [Related]
10. Gadd45a deficiency accelerates BCR-ABL driven chronic myelogenous leukemia.
Mukherjee K; Sha X; Magimaidas A; Maifrede S; Skorski T; Bhatia R; Hoffman B; Liebermann DA
Oncotarget; 2017 Feb; 8(7):10809-10821. PubMed ID: 28086219
[TBL] [Abstract][Full Text] [Related]
11. Expression of the ETS transcription factor GABPα is positively correlated to the BCR-ABL1/ABL1 ratio in CML patients and affects imatinib sensitivity in vitro.
Manukjan G; Ripperger T; Santer L; von Neuhoff N; Ganser A; Schambach A; Schlegelberger B; Steinemann D
Exp Hematol; 2015 Oct; 43(10):880-90. PubMed ID: 26072332
[TBL] [Abstract][Full Text] [Related]
12. BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene.
Sharma N; Magistroni V; Piazza R; Citterio S; Mezzatesta C; Khandelwal P; Pirola A; Gambacorti-Passerini C
Mol Cancer; 2015 Jul; 14():132. PubMed ID: 26179066
[TBL] [Abstract][Full Text] [Related]
13. Examination of clinically-derived p210 BCR/ABL1 RhoGEF mutations in a murine bone marrow transplantation model of CML.
Ciccarelli BT; Hu T; Wang Q; Kim JJ; Whitehead IP
Leuk Res; 2020 Oct; 97():106440. PubMed ID: 32892149
[TBL] [Abstract][Full Text] [Related]
14. Splicing factors PTBP1 and PTBP2 promote proliferation and migration of glioma cell lines.
Cheung HC; Hai T; Zhu W; Baggerly KA; Tsavachidis S; Krahe R; Cote GJ
Brain; 2009 Aug; 132(Pt 8):2277-88. PubMed ID: 19506066
[TBL] [Abstract][Full Text] [Related]
15. Deciphering Potential Molecular Signatures to Differentiate Acute Myeloid Leukemia (AML) with
Boucher L; Sorel N; Desterke C; Chollet M; Rozalska L; Gallego Hernanz MP; Cayssials E; Raimbault A; Bennaceur-Griscelli A; Turhan AG; Chomel JC
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895120
[TBL] [Abstract][Full Text] [Related]
16. Activation of EVI1 transcription by the LEF1/β-catenin complex with p53-alteration in myeloid blast crisis of chronic myeloid leukemia.
Manachai N; Saito Y; Nakahata S; Bahirvani AG; Osato M; Morishita K
Biochem Biophys Res Commun; 2017 Jan; 482(4):994-1000. PubMed ID: 27908728
[TBL] [Abstract][Full Text] [Related]
17. Differential Regulation of Telomeric Complex by
Deregowska A; Pepek M; Pruszczyk K; Machnicki MM; Wnuk M; Stoklosa T
Genes (Basel); 2020 Sep; 11(10):. PubMed ID: 33003326
[TBL] [Abstract][Full Text] [Related]
18. Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis.
Okabe S; Tauchi T; Nakajima A; Sashida G; Gotoh A; Broxmeyer HE; Ohyashiki JH; Ohyashiki K
Stem Cells Dev; 2007 Jun; 16(3):503-14. PubMed ID: 17610380
[TBL] [Abstract][Full Text] [Related]
19. Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment.
Oaxaca DM; Yang-Reid SA; Ross JA; Rodriguez G; Staniswalis JG; Kirken RA
Tumour Biol; 2016 Sep; 37(9):12643-12654. PubMed ID: 27444277
[TBL] [Abstract][Full Text] [Related]
20. Cantharidin Overcomes Imatinib Resistance by Depleting BCR-ABL in Chronic Myeloid Leukemia.
Sun X; Cai X; Yang J; Chen J; Guo C; Cao P
Mol Cells; 2016 Dec; 39(12):869-876. PubMed ID: 27989101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
